Photo: Grifols

Photo: Grifols

Last modified: 19/07/2012

Grifols buys 40% of the biotechnology company VCN Biosciences

The operation will enable the Catalan company to progress in the research of new agents for fighting against difficult to cure cancers. Grifols, a European leader in the sector of blood products, has been investing in medical research since 2010.

The Catalan group Grifols, which specialises in blood products, has announced the purchase of 40% of the capital of the biotechnology company VCN Biosciences. Since 2009, this company has been dedicated to research concerning new agents able to treat tumours that lack an effective treatment and in 2010 it won the BioEmprenedorXXI award.

The operation was carried out through Gri-Cel, a business created by the Catalan multinational company in 2010 to promote investment in research initiatives related to new fields of medicine, and will shortly involve the transfer of the VCN Biosciences offices, currently located in the Biopol'H cluster, to the corporate facilities that Grifols has in Sant Cugat del Vallès.

Grifols is the world's third biggest producer of blood products, the top European company in the sector and is present in over 100 countries.  In the first quarter of 2012, the company doubled its net profit compared with the same period of the previous year, reaching EUR 67.5 million. 


VCN Biosciences

Browse all news

Read the last newsletters

Get informed

Subscribe to the Barcelona Business newsletter if you want to receive information on the current state of the economy in Barcelona.